Galimedix, Inc. | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 06/10/2024 at 14:05, 5 months 10 days ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
BRIEF

published on 06/10/2024 at 14:05, 5 months 10 days ago

Galimedix Therapeutics réunit son conseil consultatif scientifique pour l'étude de phase 2 du GAL-101

Étude Clinique De Phase 2 Conseil Consultatif Scientifique GAL-101 Galimedix Thérapeutique DMLA Sèche
PRESS RELEASE

published on 06/10/2024 at 14:00, 5 months 10 days ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 8 months 12 days ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
BRIEF

published on 03/08/2024 at 10:05, 8 months 12 days ago

Galimedix Therapeutics dévoile des données prometteuses sur le traitement de la maladie d'Alzheimer à l'occasion de l'AD/PD™ 2024

Développement Clinique GAL-201 La Maladie D'Alzheimer Effets Neuroprotecteurs Fonction Cognitive
PRESS RELEASE

published on 03/08/2024 at 10:00, 8 months 12 days ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024
BRIEF

published on 02/28/2024 at 14:00, 8 months 21 days ago

Galimedix Therapeutics présente de nouvelles données précliniques sur le GAL-201 lors de la conférence AD/PD™ 2024

GAL-201 Maladie D'Alzheimer Préclinique AD/PD™ 2024 Galimedix Therapeutics
BRIEF

published on 02/28/2024 at 14:00, 8 months 21 days ago

Galimedix Therapeutics Presents New Preclinical Data on GAL-201 at AD/PD™ 2024 Conference

Alzheimer's Disease GAL-201 AD/PD™ 2024 Galimedix Therapeutics Preclinical
PRESS RELEASE

published on 02/28/2024 at 14:00, 8 months 21 days ago

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference
Galimedix Therapeutics to present new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model at AD/PD™ 2024 Conference, showing promise in targeting amyloid beta oligomers and protofibrils

Alzheimer's Disease GAL-201 Galimedix Therapeutics Pre-clinical Data AD/PD™ 2024 Conference
PRESS RELEASE

published on 10/25/2023 at 14:00, 1 year ago

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

Accesswire

Published on 11/21/2024 at 09:00, 47 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 12 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 22 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 47 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 47 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 46 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 47 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 47 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 32 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 37 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 49 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 40 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 27 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE